178 related articles for article (PubMed ID: 30741815)
41. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
O'Brien JM; Lewis DF
Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
[TBL] [Abstract][Full Text] [Related]
42. Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomized trials.
Suhag A; Saccone G; Berghella V
Am J Obstet Gynecol; 2015 Oct; 213(4):479-87. PubMed ID: 25797233
[TBL] [Abstract][Full Text] [Related]
43. Omega-3 fatty acid supplementation to prevent recurrent preterm birth: a randomized controlled trial.
Harper M; Thom E; Klebanoff MA; Thorp J; Sorokin Y; Varner MW; Wapner RJ; Caritis SN; Iams JD; Carpenter MW; Peaceman AM; Mercer BM; Sciscione A; Rouse DJ; Ramin SM; Anderson GD;
Obstet Gynecol; 2010 Feb; 115(2 Pt 1):234-242. PubMed ID: 20093894
[TBL] [Abstract][Full Text] [Related]
44. Re-examining the Meis Trial for Evidence of False-Positive Results.
Sibai B; Saade GR; Das AF
Obstet Gynecol; 2020 Sep; 136(3):622-627. PubMed ID: 32769653
[TBL] [Abstract][Full Text] [Related]
45. Factors Associated with Utilization of 17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth.
DeNoble AE; Wynn CE; Weaver KE; Wheeler SM; Swamy GK
Am J Perinatol; 2020 Feb; 37(3):264-270. PubMed ID: 30708392
[TBL] [Abstract][Full Text] [Related]
46. 17-alpha hydroxyprogesterone caproate and risk for venous thromboembolism during pregnancy.
Schuster M; Ananth CV; Gomez D; Huang Y; Gyamfi-Bannerman C; Wright JD; D'Alton ME; Friedman AM
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6336-6337. PubMed ID: 33855933
[TBL] [Abstract][Full Text] [Related]
47. 17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: A retrospective cohort study.
Stringer EM; Vladutiu CJ; Manuck T; Verbiest S; Ollendorff A; Stringer JS; Menard MK
Am J Obstet Gynecol; 2016 Jul; 215(1):105.e1-105.e12. PubMed ID: 26829508
[TBL] [Abstract][Full Text] [Related]
48. 17-alpha-hydroxyprogesterone caproate for maintenance tocolysis: a systematic review and metaanalysis of randomized trials.
Saccone G; Suhag A; Berghella V
Am J Obstet Gynecol; 2015 Jul; 213(1):16-22. PubMed ID: 25659469
[TBL] [Abstract][Full Text] [Related]
49. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
Manuck TA
Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068
[TBL] [Abstract][Full Text] [Related]
50. Understanding barriers to uptake of 17 alpha-hydroxyprogesterone caproate (17-OHP) in women with history of preterm birth.
Kalata M; Teter K; Wagner L; Swarr V; Witzeman K
J Matern Fetal Neonatal Med; 2021 Feb; 34(4):541-546. PubMed ID: 31006296
[No Abstract] [Full Text] [Related]
51. Evaluation the effect of 17-alpha hydroxyprogesterone caproate on gestational diabetes mellitus in pregnant women at risk for preterm birth.
Rouholamin S; Zarean E; Sadeghi L
Adv Biomed Res; 2015; 4():242. PubMed ID: 26682208
[TBL] [Abstract][Full Text] [Related]
52. Maternal characteristics influencing the development of gestational diabetes in obese women receiving 17-alpha-hydroxyprogesterone caproate.
Egerman R; Ramsey R; Istwan N; Rhea D; Stanziano G
J Obes; 2014; 2014():563243. PubMed ID: 25405027
[TBL] [Abstract][Full Text] [Related]
53. Impact of Obesity on the Rate of Recurrent Spontaneous Preterm Birth in Women Treated with 17-alpha Hydroxyprogesterone Caproate.
Hauspurg A; Lemon LS; Serra AE; Sharma S; Venkataramanan R; Caritis SN
Am J Perinatol; 2018 Jul; 35(9):809-814. PubMed ID: 29294501
[TBL] [Abstract][Full Text] [Related]
54. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery.
Saghafi N; Khadem N; Mohajeri T; Shakeri MT
J Obstet Gynaecol Res; 2011 Oct; 37(10):1342-5. PubMed ID: 21564406
[TBL] [Abstract][Full Text] [Related]
56. Vaginal progesterone, oral progesterone, 17-OHPC, cerclage, and pessary for preventing preterm birth in at-risk singleton pregnancies: an updated systematic review and network meta-analysis.
Jarde A; Lutsiv O; Beyene J; McDonald SD
BJOG; 2019 Apr; 126(5):556-567. PubMed ID: 30480871
[TBL] [Abstract][Full Text] [Related]
57. Disparities in 17-Hydroxyprogesterone Caproate Offer and Uptake in Pregnancies at a Risk of Preterm Birth.
Berhie SH; Riley LE; Bryant AS
Am J Perinatol; 2019 Aug; 36(10):1066-1071. PubMed ID: 30508869
[TBL] [Abstract][Full Text] [Related]
58. 17-Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta-analysis.
Combs CA; Schuit E; Caritis SN; Lim AC; Garite TJ; Maurel K; Rouse D; Thom E; Tita AT; Mol B;
BJOG; 2016 Apr; 123(5):682-90. PubMed ID: 26663620
[TBL] [Abstract][Full Text] [Related]
59. What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.
Caritis SN; Feghali MN; Grobman WA; Rouse DJ;
Semin Perinatol; 2016 Aug; 40(5):273-80. PubMed ID: 27105940
[TBL] [Abstract][Full Text] [Related]
60. Defining the clinical response to 17-alpha hydroxyprogesterone caproate.
Caritis SN; Hauspurg A; Venkataramanan R; Lemon L
Am J Obstet Gynecol; 2018 Dec; 219(6):623-625. PubMed ID: 30171841
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
